september 10, 2019
Designation Underscores Urgent Need for New Antifungals Targeting Multidrug-Resistant Pathogens SAN DIEGO – Sept. 9, 2019 – Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral...


Ny test kan afsløre farlige modermærker
14. februar 2020
Brainy Days – rejs med ind i hjernen
10. februar 2020
Astma programmeres tidligt i livet
7. februar 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge